1965, 505
Book
Presidential Studies Quarterly, ISSN 0360-4918, 09/2017, Volume 47, Issue 3, pp. 561 - 573
The unitary executive theory first went mainstream during the George W. Bush administration as the president's justification for exercising broad executive...
Barack Obama | unitary executive theory | presidential power | George W. Bush | separation of powers | Donald J. Trump | Article II powers | executive power | Federalist Papers | POLITICAL SCIENCE | POWER | Political power | Law | Terrorism | American history | Criticism | Executive orders | Constitutional law | Studies | Presidential elections | Presidential powers | Federalism | Immigration | Rhetoric | Judges & magistrates | Presidents | Executive order
Barack Obama | unitary executive theory | presidential power | George W. Bush | separation of powers | Donald J. Trump | Article II powers | executive power | Federalist Papers | POLITICAL SCIENCE | POWER | Political power | Law | Terrorism | American history | Criticism | Executive orders | Constitutional law | Studies | Presidential elections | Presidential powers | Federalism | Immigration | Rhetoric | Judges & magistrates | Presidents | Executive order
Journal Article
Nature Genetics, ISSN 1061-4036, 2012, Volume 44, Issue 9, pp. 1060 - 1065
Colletotrichum species are fungal pathogens that devastate crop plants worldwide. Host infection involves the differentiation of specialized cell types that...
SECRETED PROTEINS | SEQUENCE | GENETICS & HEREDITY | GENE-EXPRESSION | BLAST FUNGUS | HIGGINSIANUM | DEGRADATION | DIVERGENCE | GRAMINICOLA | CELLULOSE | ANTHRACNOSE | Colletotrichum - genetics | Gene Expression Regulation, Fungal | Colletotrichum - growth & development | Plant Diseases - microbiology | Gene Expression Profiling | Mitosporic Fungi - pathogenicity | Transcriptome - genetics | Phylogeny | Sequence Analysis, DNA | Arabidopsis - microbiology | Colletotrichum - pathogenicity | Genome, Fungal - genetics | Host-Pathogen Interactions - genetics | Gene Expression Regulation, Developmental | Models, Biological | Mitosporic Fungi - genetics | Mitosporic Fungi - growth & development | Plant Diseases - genetics | Cluster Analysis | Fungi, Phytopathogenic | Genetic aspects | Proteins | Cellulase | Genomics | Colleges & universities | Ribosomal DNA | Genetics | Infections | Genomes | Grants | Chromosomes | Life Sciences
SECRETED PROTEINS | SEQUENCE | GENETICS & HEREDITY | GENE-EXPRESSION | BLAST FUNGUS | HIGGINSIANUM | DEGRADATION | DIVERGENCE | GRAMINICOLA | CELLULOSE | ANTHRACNOSE | Colletotrichum - genetics | Gene Expression Regulation, Fungal | Colletotrichum - growth & development | Plant Diseases - microbiology | Gene Expression Profiling | Mitosporic Fungi - pathogenicity | Transcriptome - genetics | Phylogeny | Sequence Analysis, DNA | Arabidopsis - microbiology | Colletotrichum - pathogenicity | Genome, Fungal - genetics | Host-Pathogen Interactions - genetics | Gene Expression Regulation, Developmental | Models, Biological | Mitosporic Fungi - genetics | Mitosporic Fungi - growth & development | Plant Diseases - genetics | Cluster Analysis | Fungi, Phytopathogenic | Genetic aspects | Proteins | Cellulase | Genomics | Colleges & universities | Ribosomal DNA | Genetics | Infections | Genomes | Grants | Chromosomes | Life Sciences
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9949, pp. 1196 - 1205
Summary Background Whether initial treatment for Parkinson's disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors...
Internal Medicine | Monoamine Oxidase Inhibitors - therapeutic use | Levodopa - therapeutic use | Humans | Middle Aged | Monoamine Oxidase - drug effects | Dopamine Agonists - therapeutic use | Male | Treatment Outcome | Parkinson Disease - drug therapy | Antiparkinson Agents - therapeutic use | Animals | Aged, 80 and over | Female | Aged | Drug Therapy, Combination | Parkinson's disease | Enzyme inhibitors | Dopamine | Agonists | Drug therapy | Comparative analysis | Dopa | Studies | Inhibitor drugs | Mortality | Older people | Parkinsons disease
Internal Medicine | Monoamine Oxidase Inhibitors - therapeutic use | Levodopa - therapeutic use | Humans | Middle Aged | Monoamine Oxidase - drug effects | Dopamine Agonists - therapeutic use | Male | Treatment Outcome | Parkinson Disease - drug therapy | Antiparkinson Agents - therapeutic use | Animals | Aged, 80 and over | Female | Aged | Drug Therapy, Combination | Parkinson's disease | Enzyme inhibitors | Dopamine | Agonists | Drug therapy | Comparative analysis | Dopa | Studies | Inhibitor drugs | Mortality | Older people | Parkinsons disease
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 10/2013, Volume 188, Issue 8, pp. e13 - e64
textabstractBackground: Pulmonary rehabilitation is recognized as a core component of themanagement of individuals with chronic respiratory disease. Since the...
AIR-FLOW LIMITATION | FUNCTIONAL EXERCISE CAPACITY | 6-MINUTE WALK DISTANCE | RANDOMIZED CONTROLLED-TRIAL | NEUROMUSCULAR ELECTRICAL-STIMULATION | INSPIRATORY MUSCLE STRENGTH | exacerbation | outcomes | INTENSIVE-CARE-UNIT | RESPIRATORY SYSTEM | pulmonary rehabilitation | QUALITY-OF-LIFE | behavior | CRITICALLY-ILL PATIENTS | MINIMAL IMPORTANT DIFFERENCE | COPD | CRITICAL CARE MEDICINE | Bronchodilator Agents - therapeutic use | Lung Diseases - rehabilitation | Humans | Pulmonary Disease, Chronic Obstructive - rehabilitation | Lung - physiopathology | Lung Diseases - physiopathology | Lung Diseases - therapy | Pulmonary Disease, Chronic Obstructive - physiopathology | Motor Activity | Exercise Therapy
AIR-FLOW LIMITATION | FUNCTIONAL EXERCISE CAPACITY | 6-MINUTE WALK DISTANCE | RANDOMIZED CONTROLLED-TRIAL | NEUROMUSCULAR ELECTRICAL-STIMULATION | INSPIRATORY MUSCLE STRENGTH | exacerbation | outcomes | INTENSIVE-CARE-UNIT | RESPIRATORY SYSTEM | pulmonary rehabilitation | QUALITY-OF-LIFE | behavior | CRITICALLY-ILL PATIENTS | MINIMAL IMPORTANT DIFFERENCE | COPD | CRITICAL CARE MEDICINE | Bronchodilator Agents - therapeutic use | Lung Diseases - rehabilitation | Humans | Pulmonary Disease, Chronic Obstructive - rehabilitation | Lung - physiopathology | Lung Diseases - physiopathology | Lung Diseases - therapy | Pulmonary Disease, Chronic Obstructive - physiopathology | Motor Activity | Exercise Therapy
Journal Article
Nature Genetics, ISSN 1061-4036, 08/2013, Volume 45, Issue 8, pp. 868 - 876
Genome-wide association studies (GWAS) have previously identified 13 loci associated with risk of chronic lymphocytic leukemia or small lymphocytic lymphoma...
BREAST-CANCER | LINKAGE DISEQUILIBRIUM | AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME | TERT-CLPTM1L LOCUS | GENETICS & HEREDITY | NON-HODGKIN-LYMPHOMA | FAS GENE-MUTATIONS | COMMON VARIATION | CANCER SUSCEPTIBILITY LOCI | RECOMBINATION HOTSPOTS | EPIDEMIOLOGIC RESEARCH | Chromosomes, Human, Pair 2 | Genetic Predisposition to Disease | Genome-Wide Association Study | Recombination, Genetic | Humans | Risk | Polymorphism, Single Nucleotide | Genetic Loci | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Case-Control Studies | Linkage Disequilibrium | Chronic lymphocytic leukemia | Genetic susceptibility | Genetic variation | Physiological aspects | Genetic aspects | Research | Risk factors | Studies | Medical research | Genomes | Epidemiology | Meta-analysis | Leucèmia limfocítica crònica | Genomics | Genòmica | Medical and Health Sciences | Medicin och hälsovetenskap
BREAST-CANCER | LINKAGE DISEQUILIBRIUM | AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME | TERT-CLPTM1L LOCUS | GENETICS & HEREDITY | NON-HODGKIN-LYMPHOMA | FAS GENE-MUTATIONS | COMMON VARIATION | CANCER SUSCEPTIBILITY LOCI | RECOMBINATION HOTSPOTS | EPIDEMIOLOGIC RESEARCH | Chromosomes, Human, Pair 2 | Genetic Predisposition to Disease | Genome-Wide Association Study | Recombination, Genetic | Humans | Risk | Polymorphism, Single Nucleotide | Genetic Loci | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Case-Control Studies | Linkage Disequilibrium | Chronic lymphocytic leukemia | Genetic susceptibility | Genetic variation | Physiological aspects | Genetic aspects | Research | Risk factors | Studies | Medical research | Genomes | Epidemiology | Meta-analysis | Leucèmia limfocítica crònica | Genomics | Genòmica | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2008, Volume 359, Issue 8, pp. 789 - 799
A genomewide screen of patients with myopathy who were taking high-dose simvastatin (80 mg per day) showed a strong association between myopathy and variants...
MEDICINE, GENERAL & INTERNAL | POLYMORPHISMS | EFFICACY | SAFETY | TRANSPORTING POLYPEPTIDE 1B1 | SIMVASTATIN | CYP3A4 | ASSOCIATION | ATORVASTATIN | Simvastatin - therapeutic use | Simvastatin - adverse effects | Humans | Middle Aged | Diabetes Mellitus - drug therapy | Genotype | Male | Risk | Genetic Markers | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Myocardial Infarction - drug therapy | Arterial Occlusive Diseases - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Aged | Myocardial Infarction - prevention & control | Polymorphism, Single Nucleotide | Chromosomes, Human, Pair 12 | Muscular Diseases - chemically induced | Muscular Diseases - genetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Complications and side effects | Analysis | Muscle diseases | Genetic aspects | Dosage and administration | Single nucleotide polymorphisms | Risk factors | Statins | Drug therapy | Kinases | Drug dosages | Cholesterol | Index Medicus | Abridged Index Medicus | MEDICIN OCH HÄLSOVETENSKAP | Single Nucleotide | genetics | Arterial Occlusive Diseases | pharmacokinetics | Muscular Diseases | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Chromosomes | MEDICAL AND HEALTH SCIENCES | Human | drug therapy | chemically induced | Simvastatin | prevention & control | Diabetes Mellitus | Myocardial Infarction | Pair 12 | Organic Anion Transporters | adverse effects | therapeutic use | Polymorphism
MEDICINE, GENERAL & INTERNAL | POLYMORPHISMS | EFFICACY | SAFETY | TRANSPORTING POLYPEPTIDE 1B1 | SIMVASTATIN | CYP3A4 | ASSOCIATION | ATORVASTATIN | Simvastatin - therapeutic use | Simvastatin - adverse effects | Humans | Middle Aged | Diabetes Mellitus - drug therapy | Genotype | Male | Risk | Genetic Markers | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Myocardial Infarction - drug therapy | Arterial Occlusive Diseases - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Aged | Myocardial Infarction - prevention & control | Polymorphism, Single Nucleotide | Chromosomes, Human, Pair 12 | Muscular Diseases - chemically induced | Muscular Diseases - genetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Complications and side effects | Analysis | Muscle diseases | Genetic aspects | Dosage and administration | Single nucleotide polymorphisms | Risk factors | Statins | Drug therapy | Kinases | Drug dosages | Cholesterol | Index Medicus | Abridged Index Medicus | MEDICIN OCH HÄLSOVETENSKAP | Single Nucleotide | genetics | Arterial Occlusive Diseases | pharmacokinetics | Muscular Diseases | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Chromosomes | MEDICAL AND HEALTH SCIENCES | Human | drug therapy | chemically induced | Simvastatin | prevention & control | Diabetes Mellitus | Myocardial Infarction | Pair 12 | Organic Anion Transporters | adverse effects | therapeutic use | Polymorphism
Journal Article